Saturday 17 October 2026
Export CTXR’s income statement to Excel — free account
Citius Pharmaceuticals, Inc.
CTXR Healthcare Biotechnology
In the quarter to June 2026, EPS grew 57.5% and free cash flow fell 60.5%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
0.46
0.00
0.00%
Follow CTXR
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | 0.00 | 0.00 | 0.00 |
P/S ratio |
— | 0.00 | 0.00 | 0.00 | |
P/FCF ratio |
— | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
— | (1.29) | (15.49) | (1.84) | |
P/B ratio |
— | 0.18 | 0.29 | 0.21 | |
Price to Tangible BV |
— | 0.20 | 0.34 | 0.24 | |
EV/Sales |
— | 0.00 | 0.00 | 0.00 | |
EV/EBITDA |
— | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
— | (0.27) | (0.50) | (0.15) | |
EV/FCF |
— | (0.27) | (0.50) | (0.15) | |
Quick Ratio |
0.09 | 0.31 | 0.10 | 0.34 | |
Current Ratio |
0.62 | 0.99 | 0.58 | 0.84 | |
Net Debt/EBITDA |
0.51 | 0.91 | 0.15 | 1.08 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 4.51% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.08 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.49 | 1.58 | 0.06 | 0.98 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
(88.35) | (58.00) | (975.60) | (50.63) | |
Research and Development Expense of Revenue |
0.00% | 40.56% | 97.97% | 70.55% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 253.57% | 1,810.08% | 666.74% | |
Intangible Assets out of Total Assets |
0.07 | 0.07 | 0.07 | 0.07 | |
Share Based Compensation of Revenue |
0.00% | 108.52% | 227.21% | 255.10% | |
Graham Net Nets |
— | (0.54) | (1.58) | (1.44) | |
Graham Number |
— | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
— | (319.44%) | (241.29%) | (280.59%) | |
Free Cash Flow Yield |
— | (207.82%) | (156.94%) | (218.47%) | |
Revenue per Share |
0.00 | 0.18 | 0.07 | 0.06 | |
Operating CF per Share |
(1.07) | (0.61) | (0.06) | (0.33) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(1.07) | (0.61) | (0.06) | (0.33) | |
Cash per Share |
0.38 | 0.36 | 0.21 | 0.65 | |
Shareholders Equity per Share |
7.01 | 4.35 | 3.09 | 2.90 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
7.01 | 4.35 | 3.09 | 2.90 | |
Free Cash Flow |
(11.88) | (13.01) | (1.30) | (8.68) | |
Working Capital |
(16.98) | (0.26) | (23.33) | (8.32) | |
Net Current Asset Value |
(25.48) | (8.98) | (31.77) | (23.02) | |
EV/EBIT |
— | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
— | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
— | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
9.31 | 9.19 | 9.41 | 9.07 | |
Average Inventory |
15.28 | 18.51 | 19.00 | 19.92 | |
Average Assets |
123.79 | 130.55 | 127.01 | 134.97 | |
Average Common Equity |
75.81 | 81.19 | 66.33 | 71.73 |
Columns are period end dates